1-20 of 20
Li Meng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Clinical Trials & Observations
Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Yanli Zhang, Na Xu, Robert Peter Gale, Weiming Li, Xiaoli Liu, Huanling Zhu, Ling Pan, Yunfan Yang, Hai Lin, Xin Du, Rong Liang, Chunyan Chen, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li’e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (18): 1951–1961.
https://doi.org/10.1182/blood.2024024761
Published: 2024
Includes: Supplemental data
Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Suning Chen, Yanli Zhang, Na Xu, Hui Sun, Li Weiming, Yunfan Yang, Zunmin Zhu, Minghui Duan, Sixuan Qian, Yu Zhu, Jianmin Luo, Xiaodong Wang, Wei Yang, Weiying Gu, Fei Li, Bingcheng Liu, Yunxiao Xu, Zhenfang Liu, Chunling Wang, Yirong Jiang, Li Meng, Qin Wen, Yanli Xu, Xingli Zou, Wei Wang, Yan Xue, Hao Xu, Kehong Bi, Fuling Zhou, Liangming Ma, Rong Fu, Guifang Ouyang, Kaiyang Ding, Depei Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1797.
https://doi.org/10.1182/blood-2023-179073
Published: 2023
Journal Articles

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Li Weiming, Yanli Zhang, Zhiwei Wu, Qin Wen, Qing Leng, Shuting Wu, Xiaodong Wang, Shiming Chen, Guolin Yuan, Sixuan Qian, Suning Chen, Daozi Jiang, Lianjun Diao, Zhenfang Xi, Hui Wu, Hui Sun, Lijie Yang, Hongjuan Wang, Xuefang Zhang, Yanli Xu, Xielan Zhao, Na Xu, Li Meng, Zunmin Zhu, Youfang Zhao, Meifang Su, Zhuangzhi Yang, Chuancai Liu, Danlei Han, Yu Hu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3171.
https://doi.org/10.1182/blood-2023-179142
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib

Yuntao Liu, Yunfan Yang, Hui Sun, Li Meng, Hai Lin, Chunyan Chen, Jianda Hu, Xuliang Shen, Minghui Duan, Yanli Zhang, Dilinazi Abulaiti, Jinghua Wang, Hongqian Zhu, Luoming Hua, Qing Leng, Chun Zhang, Lili Sun, Weiming Li, Huanling Zhu, Bingcheng Liu, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6367.
https://doi.org/10.1182/blood-2023-190780
Published: 2023
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Qiuxia Lv, Qiuxia Yu, Yang Cao, Jue Wang, Yicheng Zhang, Gaoxiang Wang, Zhenya Hong, Li Meng
Journal: Blood
Blood (2022) 140 (Supplement 1): 11688–11689.
https://doi.org/10.1182/blood-2022-157416
Published: 2022
Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Sen Yang, Xiaoshuai Zhang, Yanli Zhang, Xin Du, Jianyu Weng, Huanling Zhu, Ling Pan, Yun-fan Yang, Li Meng, Zhenfang Liu, Xiaoli Liu, Na Xu, Chunyan Chen, Xiaodong WANG, Rong Liang, Jian Huang, Guohui Li, Chunshui Liu, Hai Lin, Jianda Hu, Li Fei, Bingcheng Liu, Weiming Li, Zhuogang Liu, Wei Yang, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 815–817.
https://doi.org/10.1182/blood-2022-166855
Published: 2022
Journal Articles

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

Zhenya Hong, Zhi Yang, Xiaoxi Zhou, Gaoxiang Wang, Mi Zhou, Yingzi Zhang, Peiling Zhang, Jinjin Huang, Li Meng, Haitao Ruan, Min Xiao, Yunyan Li, Linling Wang, Meiling Wang, Wei Zhu, Qianzhen Zhang, Junjie Shen, Jianfeng Zhou, Cheng Qian, Liang Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 4625–4626.
https://doi.org/10.1182/blood-2022-162134
Published: 2022
Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yunfan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9620–9623.
https://doi.org/10.1182/blood-2022-166431
Published: 2022
Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9637–9639.
https://doi.org/10.1182/blood-2022-168703
Published: 2022
Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3891–3894.
https://doi.org/10.1182/blood-2022-168812
Published: 2022
Journal Articles

Efficacy and Safety of Generic Dasatinib As First-Line Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase: Final Analysis with 2-Year Follow-up

Jie Jin, Li Meng, Wenjuan Yu, Peng Liu, Xin Du, Jin Lou, Weiguang Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3616.
https://doi.org/10.1182/blood-2021-150197
Published: 2021
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Jiang Qian, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yongping Song, Gongli Zhang, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yujun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3598.
https://doi.org/10.1182/blood-2021-153937
Published: 2021
Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Di Wang, Jue Wang, Guang Hu, Wen Wang, Yi Xiao, Haodong Cai, Lijun Jiang, Li Meng, Yongkun Yang, Xiaoxi Zhou, Zhenya Hong, Zheng Yao, Min Xiao, Liting Chen, Xia Mao, Li Zhu, Jin Wang, Lugui Qiu, Chunrui Li, Jianfeng Zhou
Journal: Blood
Blood (2021) 137 (21): 2890–2901.
https://doi.org/10.1182/blood.2020008936
Published: 2021
Includes: Supplemental data
Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, MD, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, MD, Weiming Li, PhD, Xiaoli Liu, Na Xu, Yongping Song, MD, Yanli Zhang, Li Meng, MDPhD, Zhenya Hong, MDPhD, Bingcheng Liu, Shan Zeng, Lichuang Men, Yan Li, MD, Suning Chen, Mengxing Xue, PhD, Huanling Zhu, MD, He Li, Xin Du, Jin Lou, MD, Xiaohan Zhang, Yang Liang, MD, Yujun Dai, MD PhD, Ming Lu, PhD, Hengbang Wang, Jiao JI, PhD MD, Changai Yue, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142142
Published: 2020
Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 929.
https://doi.org/10.1182/blood-2019-128468
Published: 2019
Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2027.
https://doi.org/10.1182/blood-2019-131818
Published: 2019
Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Ryan D. Morin, PhD BSc, MSc, Anca Prica, MD, Vishal Kukreti, MD, Robert Kridel, PhD MD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, BSc, Miguel Alcaide, PhD, Rashmi S. Goswami, BSc, MD PhD FRCPC, Jan M.A. Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, PhD MD, FRACP, FRCPA, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4610.
https://doi.org/10.1182/blood-2018-99-117333
Published: 2018
Journal Articles

Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study

Qian Jiang, MD, Jianda Hu, MD PhD, Fang Zheng, Xin Du, Li Meng, Depei Wu, MD PhD, Bingcheng Liu, Zhuogang Liu, Jun Ma, MD, Ming Hou, MD PhD, Sixuan Qian, Qingshu Zeng, Yu Hu, Xiaojun Huang
Journal: Blood
Blood (2016) 128 (22): 5439.
https://doi.org/10.1182/blood.V128.22.5439.5439
Published: 2016